Pfizer/BioNTech COVID jab to be sold privately in UK
pharmaphorum
FEBRUARY 11, 2024
MHRA license change means people in GB will be able to buy Pfizer’s COVID-19 vaccine Comirnaty at retail pharmacies from March
pharmaphorum
FEBRUARY 11, 2024
MHRA license change means people in GB will be able to buy Pfizer’s COVID-19 vaccine Comirnaty at retail pharmacies from March
Fierce Healthcare
FEBRUARY 11, 2024
A new year brings a new approach to tracking health tech and digital health investments. | Each week, Fierce Healthcare will publish a roundup of health tech and digital health financing rounds.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharm
FEBRUARY 11, 2024
Webinar Date/Time: Tue, Mar 5, 2024 2:00 PM EST
Med Ed 101
FEBRUARY 11, 2024
With many insulin formulations on the market, it can be hard to differentiate between similar-acting products and what the best choice may be for our patients. One question raised is what the differences between Novolog versus Fiasp are due to both being insulin aspart formulations. The main difference is right in the name of Fiasp. […] The post Novolog Versus Fiasp Insulin Comparison appeared first on Med Ed 101.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The FDA Law Blog
FEBRUARY 11, 2024
By Larry K. Houck — With apologies to David Letterman, who introduced the first Top Ten List on Late Night with David Letterman on September 18, 1985, we present “Marijuana: Top Ten Reasons for Descheduling, Rescheduling or Not.”* The wide range of assertions supporting or opposing Health and Human Services’ (“HHS’”) recommendation that the Drug Enforcement Administration (“DEA”) reschedule cannabis federally from schedule I to schedule III would lead an outsider to conclude that commenters are
Let's personalize your content